Cochlear announces earnings upgrade
Wednesday, 14 December, 2005
Bionic ear specialist Cochlear (ASX:COH) has announced an upgrade of its guidance on core earnings for the 2005-06 financial year to AUD$80 million.
The company gave previous guidance that its core earnings for the year would increase by 20 per cent from 2005 financial year levels to about $70 million. Stronger sales could now lead to an increase of 37 per cent over the last year, the company said, with core earnings in the order of $80 million.
"Sales momentum, which picked up the second half of the last financial year, has continued to be stronger than predicted, particularly from the new Nucleus Freedom Cochlear Implant System released from April 2005," said Cochlear CEO Chris Roberts in a statement.
The company will provide further details of its first half results on February 14, 2006.
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
